Cargando…

Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer

SIMPLE SUMMARY: Resistance to tamoxifen treatment is an obstacle for ER+ve breast cancer therapy. The overexpression of c-MYC is a known driver of cancer progression and is associated with tamoxifen resistance. Through mediating the up-regulation of ribosome biogenesis and alteration of the transcri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsoi, Ho, You, Chan-Ping, Leung, Man-Hong, Man, Ellen P. S., Khoo, Ui-Soon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909264/ https://www.ncbi.nlm.nih.gov/pubmed/35267559 http://dx.doi.org/10.3390/cancers14051251

Ejemplares similares

Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2023)

Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2021)

Modulating the Activity of Androgen Receptor for Treating Breast Cancer
por: You, Chan-Ping, et al.
Publicado: (2022)

Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer
por: You, Chan-Ping, et al.
Publicado: (2022)

KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer
por: Tsoi, Ho, et al.
Publicado: (2021)

Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer
por: Gong, Chun, et al.
Publicado: (2020)

A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
por: Leung, Man-Hong, et al.
Publicado: (2020)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

All these screens that we’ve done: how functional genetic screens have informed our understanding of ribosome biogenesis
por: Harold, Cecelia M.
Publicado: (2023)

Repurposing hyperpolarization‐activated cyclic nucleotide‐gated channels as a novel therapy for breast cancer
por: Mok, Ka‐Chun, et al.
Publicado: (2021)

Ribosome Biogenesis in Archaea
por: Londei, Paola, et al.
Publicado: (2021)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Ribosome Biogenesis and Cancer: Overview on Ribosomal Proteins
por: Pecoraro, Annalisa, et al.
Publicado: (2021)

The Ribosome Biogenesis—Cancer Connection
por: Penzo, Marianna, et al.
Publicado: (2019)

Inhibiting eukaryotic ribosome biogenesis
por: Awad, Dominik, et al.
Publicado: (2019)

Increasing Complexity of Ribosomes and Their Biogenesis
por: Lindahl, Lasse
Publicado: (2022)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model
por: De Oliveira Andrade, Fabia, et al.
Publicado: (2019)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

Shaping the Nascent Ribosome: AAA-ATPases in Eukaryotic Ribosome Biogenesis
por: Prattes, Michael, et al.
Publicado: (2019)

Evolution of the holozoan ribosome biogenesis regulon
por: Brown, Seth J, et al.
Publicado: (2008)

Ribosome biogenesis: Achilles heel of cancer?
por: van Sluis, Marjolein, et al.
Publicado: (2014)

The Circadian Clock Coordinates Ribosome Biogenesis
por: Jouffe, Céline, et al.
Publicado: (2013)

snoRNPs: Functions in Ribosome Biogenesis
por: Ojha, Sandeep, et al.
Publicado: (2020)

Ribosome Biogenesis Alterations in Colorectal Cancer
por: Nait Slimane, Sophie, et al.
Publicado: (2020)

RNase III, Ribosome Biogenesis and Beyond
por: Lejars, Maxence, et al.
Publicado: (2021)

Eukaryotic Ribosome Biogenesis: The 40S Subunit
por: Moraleva, A. A., et al.
Publicado: (2022)

Eukaryotic Ribosome Biogenesis: The 60S Subunit
por: Moraleva, A. A., et al.
Publicado: (2022)

SUMO pathway is required for ribosome biogenesis
por: Ryu, Hong-Yeoul
Publicado: (2022)

The Effects of Deregulated Ribosomal Biogenesis in Cancer
por: Lu, Yiwei, et al.
Publicado: (2023)

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer
por: Perez White, Bethany, et al.
Publicado: (2013)

Ribosome Biogenesis Serves as a Therapeutic Target for Treating Endometriosis and the Associated Complications
por: Chang, Cherry Yin-Yi, et al.
Publicado: (2022)

Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex
por: Lin, Yu-Ling, et al.
Publicado: (2016)

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells
por: Kim, Seung-Su, et al.
Publicado: (2020)

A ribosome-anchored chaperone network that facilitates eukaryotic ribosome biogenesis
por: Albanèse, Véronique, et al.
Publicado: (2010)

Reconstitution of 30S ribosomal subunits in vitro using ribosome biogenesis factors
por: Tamaru, Daichi, et al.
Publicado: (2018)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v1bvjef8omvlf4q7fhkkqe1j0h